Randomized trial of delta-9-tetrahydrocannabinol (THC) versus placebo to augment the effects of prolonged exposure therapy on fear extinction learning in post-traumatic stress disorder: Study rationale and protocol
Contemporary Clinical Trials · 2026-01 · 160 · 108148
DOI: 10.1016/j.cct.2025.108148 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2026-01. Verfasst von Christine A Rabinak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Wayne State University Eugene Applebaum College of Pharmacy & Health Sciences, 259 Mack Ave., Detroit, MI 48201, USA. Hauptthemen laut MEDLINE: Stress Disorders, Post-Traumatic, Dronabinol, Extinction, Psychological, Fear. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, National Institute of Mental Health, National Institute of Mental Health and Neurosciences.
Abstract (Originalsprache)
BACKGROUND: Prolonged exposure (PE) therapy is effective for PTSD, yet dropout and partial response remain concerning. Preclinical and human studies suggest Δ9-tetrahydrocannabinol (THC) enhances fear extinction and recall through brain cannabinoid receptor activation in fear processing. OBJECTIVE: Examine whether synthetic THC (dronabinol) augments PE effectiveness. DESIGN: Double-blind, placebo-controlled, trial with treatment-seeking PTSD patients (ages 18-60) randomized to 7.5 mg THC (n = 30) or placebo (n = 30). Randomization after sessions 1-2 (psychoeducation) ensures covariate-adaptive balance before the first medicated session. THC/placebo administered before PE sessions 3-6 of 10 total sessions so dosing coincided with extinction-learning sessions. SETTING: Wayne State University with remote PE delivery via Emory University. PARTICIPANTS: Adults with PTSD (CAPS-5 ≥ 25) excluding for severe mental illness, substance use disorders, or contraindications to THC. INTERVENTIONS: PE therapy (10 sessions, up to 3 times / week) with THC or placebo administered 120 min before sessions to coincide with peak plasma levels. MAIN OUTCOMES: Primary: PTSD symptom severity (CAPS-5, PCL-5). Secondary: fMRI brain activation during fear extinction paradigms, skin conductance responses, and extinction retention measures pre/post-treatment. STATISTICAL ANALYSIS: Intent-to-treat linear mixed-effects models accounting for therapist clustering. Neuroimaging analyzed via region-of-interest and whole-brain approaches focusing on ventromedial prefrontal cortex, hippocampus, and amygdala. DISCUSSION: THC dosing and timing is based on prior mechanistic studies that demonstrated THC-related enhancement of extinction recall and frontolimbic circuit engagement. Aligning peak THC levels with exposure sessions maximizes potential for CB1-mediated augmentation of extinction learning. If effective, this FDA-approved augmentation strategy could be rapidly implemented to improve PE outcomes. TRIAL REGISTRATION: ClinicalTrials.govNCT04080427.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Wayne State University Eugene Applebaum College of Pharmacy & Health Sciences, 259 Mack Ave., Detroit, MI 48201, USA.
- Department of Psychology, Wayne State University, 5057 Woodward Ave. Suite 7908, Detroit, MI 48202, USA.
- Joseph Maxwell Cleland Atlanta VA Medical Center, 1670 Clairmont Road, Decatur, GA 30033, USA; Emory University School of Medicine, 12 Executive Park, 3(rd) Floor, Atlanta, GA 30029, USA. Electronic address: sheila.a.m.…
Förderung
- NIMH NIH HHS
- National Institute of Mental Health
- National Institute of Mental Health and Neurosciences
Zitieren
APA
Rabinak, C. A., Kilgore, P. E., Lumley, M. A., & Rauch, S. A. M. (2026). Randomized trial of delta-9-tetrahydrocannabinol (THC) versus placebo to augment the effects of prolonged exposure therapy on fear extinction learning in post-traumatic stress disorder: Study rationale and protocol. Contemporary Clinical Trials, 160, 108148. https://doi.org/10.1016/j.cct.2025.108148
Vancouver
Rabinak CA, Kilgore PE, Lumley MA, Rauch SAM. Randomized trial of delta-9-tetrahydrocannabinol (THC) versus placebo to augment the effects of prolonged exposure therapy on fear extinction learning in post-traumatic stress disorder: Study rationale and protocol. Contemporary Clinical Trials. 2026;160:108148. doi:10.1016/j.cct.2025.108148
BibTeX
@article{Rabinak2026,
author = {Rabinak, Christine A and Kilgore, Paul E and Lumley, Mark A and Rauch, Sheila A M},
title = {Randomized trial of delta-9-tetrahydrocannabinol (THC) versus placebo to augment the effects of prolonged exposure therapy on fear extinction learning in post-traumatic stress disorder: Study rationale and protocol},
journal = {Contemporary Clinical Trials},
year = {2026},
volume = {160},
pages = {108148},
doi = {10.1016/j.cct.2025.108148}
}
EUVIMED